Sphere Fluidics appoints Kenneth Hitchner as Chairman of its Board of Directors

Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed Kenneth Hitchner, BA MBA, as Chairman of its Board of Directors. The announcement follows a series of appointments to the Company’s senior leadership team, as part of its ambitious global growth strategy.

With over 30 years in the healthcare industry, Ken brings extensive strategic advisory, M&A, underwriting and other transactional expertise. He spent much of his 28-year career at Goldman Sachs in the biopharmaceutical and medical device sectors; a member of the Global Management committee and Chairman and CEO of Asia Pacific, excluding Japan, from 2013 to 2019. Prior to this role, Ken was Goldman Sachs’ Global Head of Healthcare banking and Global Co-Head of TMT banking. Before joining Goldman Sachs, Ken was a carrier-based fighter bomber pilot for the U.S. Navy. He is currently a Board member of publicly traded Wuxi Biologics and CStone Pharmaceuticals, and a senior advisor to Wuxi Apptec. Additionally, Ken is Chairman of HH&L, a healthcare focused specialty acquisition company listed on the NYSE, and Cydar Medical. He is also a senior advisor to early-stage venture capital firm Antler.

Kenneth Hitchner, Chairman of Board of Directors, Sphere Fluidics, commented: “Sphere Fluidics is changing the face of cell line development. The Cyto-Mine® platform has transformed single cell analysis and the productivity of biopharmaceutical discovery, maximizing researchers’ productivity in finding rare or valuable cell variants that can lead to a life-changing medicine. I look forward to collaborating with the team as we drive the Company forward in this exciting next phase of commercial growth.”

Dr. Frank F Craig, CEO, Sphere Fluidics, said: “Ken’s expertise in the Financial Services industry is invaluable, his appointment will become a key asset for our Board. He has tremendous experience in positioning companies, facilitating significant fund raises and driving M&A in the Life Sciences arena. This expertise will help us in our future plans for building business value and ultimately exiting via a Trade Sale or IPO.”

For more information about Sphere Fluidics, please visit: https://spherefluidics.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Sphere Fluidics. (2023, June 28). Sphere Fluidics appoints Kenneth Hitchner as Chairman of its Board of Directors. News-Medical. Retrieved on July 20, 2024 from https://www.news-medical.net/news/20230502/Sphere-Fluidics-appoints-Kenneth-Hitchner-as-Chairman-of-its-Board-of-Directors.aspx.

  • MLA

    Sphere Fluidics. "Sphere Fluidics appoints Kenneth Hitchner as Chairman of its Board of Directors". News-Medical. 20 July 2024. <https://www.news-medical.net/news/20230502/Sphere-Fluidics-appoints-Kenneth-Hitchner-as-Chairman-of-its-Board-of-Directors.aspx>.

  • Chicago

    Sphere Fluidics. "Sphere Fluidics appoints Kenneth Hitchner as Chairman of its Board of Directors". News-Medical. https://www.news-medical.net/news/20230502/Sphere-Fluidics-appoints-Kenneth-Hitchner-as-Chairman-of-its-Board-of-Directors.aspx. (accessed July 20, 2024).

  • Harvard

    Sphere Fluidics. 2023. Sphere Fluidics appoints Kenneth Hitchner as Chairman of its Board of Directors. News-Medical, viewed 20 July 2024, https://www.news-medical.net/news/20230502/Sphere-Fluidics-appoints-Kenneth-Hitchner-as-Chairman-of-its-Board-of-Directors.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Sphere Fluidics appoints Dr. Graeme Daniels as Vice President of Sales and Marketing